Hot Investor Mandate: Asian Conglomerate Makes Investments in Early-Stage Medtech Companies Globally

20 Aug

A venture capital arm of a large Asian financial conglomerate mainly invests in the IT, communications, cultural/creative, alternative energies, biotechnology, and medical/healthcare sectors. The firm seeks to invest in commercial stage or expansion phase companies that are 3-5 years from IPO. Typical equity allocations range from US$1-3 million and can be up to US$5 million. The firm is now focused on China and South East Asia, with interest in opportunities from North America and Europe to a lesser extent.

Within healthcare, the firm is interested in all sectors of medical technology, including consumer and non-consumer products. The firm is agnostic to indications. The firm is less interested in therapeutics, but it would consider drug reformulation. The firm looks for products that are ready for commercialization or at the commercial stage and seeking growth/expansion capital.

The firm looks for a strong and experienced management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: